OBJECTIVE: To assess the effect of chronic treatment with a b b 3 -adrenoceptor agonist, CL 316,243 (CL) on serum leptin concentration in rats with diet-induced obesity (DIO) or with genetic obesity (faafa Zucker). DESIGN: Leptin concentration was measured in serum of young control rats, young rats with DIO and old control or genetically obese faafa Zucker rats, that were treated chronically with CL for 2±4 weeks in our previous studies. RESULTS: Treatment with CL reduced elevated leptin concentrations in young rats with DIO and in old mildly obese control rats to the low concentration of young lean rats. It did not alter the grossly elevated concentration in faafa rats. This effect of CL correlated well with its effect to reduce white adipocyte size, except in faafa rats. In CL-treated faafa rats, despite reductions in body fat mass and in white adipocyte size, and despite normalization of both hyperglycemia and hyperinsulinemia, the leptin concentration did not change. DISCUSSION: The reason for lack of change in leptin concentrations in faafa rats, despite shrinking of white adipocytes and partial reversal of the obesity, may be due to another defect. The large increase in white adipocyte number in these animals was not reversed by the treatment and might have contributed to elevated leptin production. In addition, all forms of leptin receptor are known to be defective in faafa rats. Since leptin is rapidly excreted in urine and leptin receptors (including a form known to be involved in leptin transport) are expressed in the kidney, we suggest that leptin excretion is impaired in the faafa rat. This impairment contributes to maintenance of an elevated concentration of leptin in its blood and prevents treatment with a b b 3 -adrenoceptor agonist from reducing this elevated concentration despite reversal of both obesity and diabetes. In addition, we suggest that CL-induced suppression of hyperphagia in faafa rats is leptin-independent and due to the large increase in thermogenesis.
propyl]-1,3-benzodioxole-2,2-dicarboxylate) reverses diet-induced obesity (DIO) and obesity due to the fatty mutation in the leptin receptor gene 4±8 ) We previously reported 5, 6 that the antiobesity effect of chronic treatment with CL is associated with shrinking of white adipocytes and with reversal of hyperphagia when this is present (in faafa rats); chronic CL-treatment does not change food intake in normophagic rats. Acute b 3 -AR stimulation is known to suppress leptin expression and secretion in white adipose tissue, 9±12 lowering its concentration in blood, and is also known to suppress food intake in a leptin-independent way. 12 We previously suggested 6 that the effect of chronic CL treatment to suppress food intake in faafa rats, but not in control or DIO rats, was due to an inability of the faafa rats to detect any b 3 -AR-mediated reduction in leptin concentration. This would stimulate food intake in normal rats and thus oppose the food intake suppressing effect of heat (generated in brown adipose tissue in response to b 3 -AR stimulation). The objective of the present study was to assess the effect of chronic b 3 -AR stimulation by CL on leptin concentration in blood of obese and lean male rats. The animals, procedures and other data are described in our previous papers. 5, 6 Rats ate chow (Agway R-M-H chow, 14.5% energy from fat) or, to induce DIO, a high-fat diet (Teklad 85418, 54% energy from partially hydrogenated vegetable oil). 5, 6 Body fat content was low in young lean control rats (5%), doubled in old control rats, tripled in young DIO rats and increased ®ve-fold in old faafa rats. 5Y6 Serum leptin concentration was correlated with total body fat content. In young rats with DIO and in old mildly obese rats control, treatment with CL reduced the leptin concentration to the low level of young lean rats (Figure 1 ). Treatment did not alter the elevated concentration in the faafa rats ( Figure 1B) or the low level in the young lean rats ( Figure 1A ). The effect of CL correlated well with its effect to reduce white adipocyte size, 5, 6 except in faafa rats. Thus, white adipocyte size in young control rats was small (0.32 AE 0.040 mg lipid per cell, n 8) and not reduced by CL, whereas white adipocyte size was about twice as large in DIO rats (0.63 AE 0.024 mg, n 8), in old control rats (0.58 AE 0.041 mg, n 8) and in faafa rats (0.65 AE 0.052 mg, n 6) and was reduced by CL. In faafa rats, despite the reduction in body fat mass and in white adipocyte size, and despite normalization of hyperglycemia and hyperinsulinemia, neither the grossly elevated leptin concentration in serum nor the greatly elevated number of white adipocytes 6 was reduced.
The lack of change in leptin concentration in the CL-treated faafa rats needs further comment. It is conceivable that the pronounced effect of b 3 -AR stimulation to suppress leptin expression in white adipose tissue, seen in normal rats, 9±12 for some reason does not occur in faafa rats. These rats are reported to have down-regulation of b 3 -adrenoceptors. 13, 14 However, the treatment did shrink the white adipocytes in two abdominal depots, normalize the hyperinsulinemia and induce a markedly hypermetabolic state. 6 Presumably enough b 3 -ARs remain functional for these responses to occur. It is possible that leptin production by extra-abdominal (mainly subcutaneous) white adipose tissue remained high in the CL-treated faafa rats. This tissue was not reduced in mass by the CL-treatment. Indeed, the elevated leptin mRNA concentration in subcutaneous (inguinal) white adipose tissue of faafa rats is not suppressed when hyperinsulinemia is normalized by three days of fasting. 15 Possibly the elevated leptin concentration in the faafa rat re¯ects the markedly increased number of white adipocytes, rather than, or in addition to, the size of these cells. We also suggest here another reason for the lack of change in the high leptin concentrations in faafa rats. All forms of leptin receptor are defective in faafa rats. 16, 17 Since leptin is rapidly concentrated in the kidney and excreted in urine, 18Y19 and leptin receptors (including a form known to be involved in leptin transport) 20 are expressed in the kidney, 21, 22 it may be that leptin excretion is impaired in the faafa rat. This impairment might contribute to maintenance of the very high level of leptin in its blood and to the failure of chronic treatment with a b 3 -adrenoceptor agonist to reduce this high level, despite reversal of both obesity and diabetes by the treatment. A similar explanation may underlie the resistance of faafa rats to the effect of acute cold exposure to lower leptin levels. 23 The only rats in which food intake was reduced by CL, were the hyperphagic faafa rats. Since the leptin level was not changed by the treatment and these rats are in any case resistant to the action of leptin, we suggest that the reason CL reversed their hyperphagia was the increase in thermogenesis it induced. 6 Figure 1 Effect of CL treatment on concentration of leptin in serum of obese and lean rats. A: Diet-induced obesity. SpragueDawley rats ate chow (Chow) or became obese while eating a high-fat diet (High-fat). They were 4 months old at the start of the study and ate a high-fat diet from time 0 to 4 weeks. Implanted osmotic minipumps were used to infuse CL (1 mg.kg 7 1 .day 7 1 ) or saline (S) during the four week period indicated by the horizontal bar. B: Genetic obesity. Zucker control (lean) or obese (faafa) rats were used. They were 8 months old at the start of the study. They were infused with CL (CL) or saline (S) from time 0. Leptin was measured in serum using a kit for rat leptin (Linco Research Labs, St Charles, MO, USA). Statistics: A shows there is a signi®cant effect of diet at 4 weeks (P ( 0.01) and a signi®cant effect of CL in rats eating a high-fat diet (P ( 0.01) but not in the rats eating chow; B shows there is a signi®cant effect of genotype (P ( 0.001) and a signi®cant effect of CL in lean rats (P ( 0.01) but not in faafa rats.
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